Basic Research in Cardiology

, Volume 80, Issue 6, pp 626–635 | Cite as

Acute effect of calcium channel blockers on adriamycin exposed isolated adult cardiocytes

  • B. Maisch
  • O. Gregor
  • M. Zeuss
  • K. Kochsiek
Original Contributions

Summary

When tested with isolated, calcium-resistant resting rat cardiocytes in an in vitro assay system, adriamycin exerted a dose-dependent cytotoxic effect which could easily be assessed by the ATP depletion of the heart cells and the loss of vitality as monitored by morphological changes (blebbing, spherical contraction). Apart from extremely high non pharmacological concentrations of verapamil and diltiazem, both calcium antagonists left the cardiocytes intact and without loss of internal ATP when given alone to the medium. Coincubation of adriamycin and verapamil or diltiazem did not increase adriamycin toxicity to the cardiocytes; instead a remarkable ATP preservation by verapamil could be demonstrated when both drugs (adriamycin and verapamil) were incubated simultaneously with the heart cells. This acute protective effect was limited in time and could no longer be detected after 9 hours. Diltiazem in coincubation experiments exerted neither a toxic nor an acute protective effect on adriamycin-exposed heart cells.

Key words

isolated adult cardiocytes adriamycin cardiotoxicity verapamil diltiazem 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Arena E, Arico M, Biondo F, D'Alessandro N, Dusonchet L, Gabbia N, Gerbasi F, Sanguedolce R, Ranse L (1975) Analysis of some probable factor responsible for adriamycin induced cardiotoxicity. Adriamycin review Part II:160–172Google Scholar
  2. 2.
    Azuma J, Sperelakis N, Hawegawa H, Tanimoto T, Vogel S, Ogura K, Awato N, Sawamura A, Horada H, Ishiyama T, Monta Y, Yamamura Y (1981) Adriamycin cardiotoxicity: Possible pathogenetic mechanisms. J Mol Cell Cardio 13:381–397CrossRefGoogle Scholar
  3. 3.
    Bachmann E, Zbinden G (1979) Effect of doxorubicin and rubidazone on respiratory function and Ca21 transport in rat heart mitochondria. Toxicol Lett 3:29–34CrossRefGoogle Scholar
  4. 4.
    Bachur NR, Gordon SL, Gee MV (1972) Anthracycline antibiotic augmentation of microsomal electron transport and free radical formation. Mol Pharmacol 13:901–910Google Scholar
  5. 5.
    Berndt H (1983) Zum Stand der Krebstherapie mit Adriamycin. (Status of adriamycin in cancer therapy.) Arch Geschwulstforsch 52(7):585–596Google Scholar
  6. 6.
    Billingham ME, Mason JW, Briston MR, Daniels JR (1978) Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treatment Rep 62:865–872Google Scholar
  7. 7.
    Binah O, Cohen IS, Rosen MR (1983) The effects of adriamycin on normal and ouabain toxic canine Purkinje and ventricular muscle fibers. Circ Res 53:655–662PubMedGoogle Scholar
  8. 8.
    Bristow MR, Thompson PD, Martin RP, Mason JW, Billingham ME, Harrison DC (1978) Early anthracycline cardiotoxicity. Am J Med 65:823–832CrossRefPubMedGoogle Scholar
  9. 9.
    Bristow MR (1980) Anthracycline cardiotoxicity. In: Bristow MR (ed) Drug-induced heart disease. Elsevier/North-Holland Biomedical Press pp 191–215Google Scholar
  10. 10.
    Bristow MR (1980) Protection against doxorubicin cardiomyopathy in rabbits by coenzyme Q10: Evidence for non-specific myocardial preservation. Biomed Clin Aspects coenzyme 2:179–188Google Scholar
  11. 11.
    Bristow MR, Ginsburg R, Laser J, McAuley B, Minobe W (1984) Tissue response selectivity of calcium antagonists is not due to heterogeneity of (3H) nitrendipine binding sites. Br J Pharmacol 82(2):309–320PubMedGoogle Scholar
  12. 12.
    Buehner R, Biedert S, Miura D (1980) Experimentelle Untersuchungen zur Klärung der Pathogenese der durch Adriamycin induzierten Kardiomyopathie. Arzneimittel-Forsch 30(7):1065–1070Google Scholar
  13. 13.
    Caroni P, Villani F, Carafoli E (1981) The cardiotoxic antibiotic doxorubicin inhibits the Na+/Ca2+ exchange of dog heart sarcolemmal vesicles. FEBS Lett 130:184–186PubMedGoogle Scholar
  14. 14.
    Daniels JR, Margaret E, Billingham ME, Gelbert A, Bristow MR (1976) Effect of verapamil and propranolol on adriamycin-induced cardiomyopathy in rabbits. Circulation 53 & 54 (Suppl 2):70Google Scholar
  15. 15.
    Favalli L, Ferrari CC, Monti E, Piccinini F, Villani F (1981) Effect of verapamil on the relationship between calcium turnover and early cardiotoxicity of doxorubicin. IRCS Pharmacol 9(5):397–398Google Scholar
  16. 16.
    Ganapathi R, Grabowski D (1983) Enhancement of sensitivity to adriamycin in resistant P388 leukemia by the calmodulin inhibitor trifluoperazine. Cancer Res 43(8):3696–3699PubMedGoogle Scholar
  17. 17.
    Garbrecht M, Müllerleile U, Hanrath P, Langenstein B, Bieber K, Krüger W (1981) Eine mögliche Prävention der adriamycininduzierten Kardiomyopathie durch Kalziumantagonisten. Beitr Onkol 9:pp 43–48Google Scholar
  18. 18.
    Hauder K, Sato S (1975) Generation of free radicals of quinone group containing anticancer chemicals in RADPH-microsome system as evidenced by initiation of sulfize oxidation. Gann 66:43–47PubMedGoogle Scholar
  19. 19.
    Ito H, Hidaka H (1983) Antitumor effect of a calmodulin antagonist on the growth of solid sarcoma-180. Cancer Lett 19(2):215–220CrossRefPubMedGoogle Scholar
  20. 20.
    Iwamoto Y, Hansen IL, Porter TH, Folkers K (1974) Inhibition of coenzyme Q10-enzymes, succinoxidase and NADH-oxidase by adriamycin and other quinons having antitumor activity. Biochem Biophys Res 58:633–638Google Scholar
  21. 21.
    Klugmann S, Klugmann FB, Decorti G, Gori D, Silvestri F, Camerini F (1980) Effects of two calcium antagonistic agents in the experimental cardiomyopathy induced by adriamycin in Swiss mice. In: Zanchetti A (ed) International Symposium on Calciumantagonism in cardiovascular therapy. Experience with Verapamil, 27–29Google Scholar
  22. 22.
    Klugmann S, Klugmann FB, Decorti G, Gori D, Silvestri F, Camerini F (1981) Adriamycin experimental cardiomyopathy in Swiss mice. Different effects of two calcium antagonistic drugs on ADM-induced cardiomyopathy. Pharmacol Res Comm 13(8):769–776Google Scholar
  23. 23.
    Lewis W, Galizi M, Puszkin S (1983) Compartmentalization of adriamycin and daunomycin in cultured chick cardiac myocytes. Effects on synthesis of contractile and cytoplasmic proteins. Circ Res 53:352–362PubMedGoogle Scholar
  24. 24.
    Maisch B (1981) Enrichment of vital adult cardiac muscle cells by continuous silica sol gradient centrifugation. Basic Res Cardiol 76:622–629PubMedGoogle Scholar
  25. 25.
    Maisch B, Wilke H, Gunzer U, Marcin S, Salzer E (1982) Antimyocardial antibodies. — A diagnostic marker in adriamycin-induced cardiomyopathy. Circulation 66(II):247Google Scholar
  26. 26.
    Maisch B, Gregor O, Zeuss M, Kochsiek K (1985) Protektive Wirkung von Kalziumantagonisten auf adriamycinexponierte isolierte Kardiozyten. Klin Wschr 63:158(A 382)CrossRefPubMedGoogle Scholar
  27. 27.
    Maisch B, Wilke H, Marcin S, Werner C, Gebhardt W (1984) Adriamycin cardiotoxicity. — An echocardiographic and immunological follow-up study. Circulation 70, part II:149Google Scholar
  28. 28.
    Marafino BJ, Giri Jr and SN (1981) Effects of nutrition, dose and verapamil treatment on the cardiotoxicity of doxorubicin. Pharmacol 23:154Google Scholar
  29. 29.
    Milei J, Busch L, Marantz H, Bolomo N (1980) Prenylamine inhibition of adriamycin cardiomyopathy in mice. Proc Am Assoc Cancer Res 21:330Google Scholar
  30. 30.
    Mizuno S, Ishida A (1982) Potentiation of Bleomycin cytotoxicity by membrane-interacting drugs and increased calcium ions. Biochem Biophys Res Comm 107:1021–1027CrossRefPubMedGoogle Scholar
  31. 31.
    Moore L, Landon EJ, Cooney DA (1977) Inhibition of the cardiac mitochondrial calcium pump by adriamycin in vitro. Biochem Med 18:131–138CrossRefPubMedGoogle Scholar
  32. 32.
    Myers CE, Mc Guire WP, Liss RH, Grotzinger K, Young RC (1977) Adriamycin: The role of lipid peroxidation in cardiac toxicity and tumor response. Science 197:165–167PubMedGoogle Scholar
  33. 33.
    Müllerleile U, Garbrecht M, Hanrath P, Bieber K, Thier W, Hossfeld DK (1983) Prävention der durch Adriamycin induzierten Kardiomyopathie mit Verapamil. Verh Deutsch Ges f inn Med 89:583–585Google Scholar
  34. 34.
    Olsen HM, Young DM, Prieur DJ, Le Roy AF, Reagan RL (1974) Electrolyte and morphologic alterations of myocardium in adriamycin treated rats. Am J Pathol 77:439–450PubMedGoogle Scholar
  35. 35.
    Powell R, Twist VW (1976) A rapid technique for the isolation and purification of adult cardiac muscle cells having respiratory control and tolerance to calcium. Biochem Biophys Res Commun 72:327–333CrossRefPubMedGoogle Scholar
  36. 36.
    Rabkin SW (1983) Interaction of external calcium concentrations and verapamil on the effects of doxorubicin (adriamycin) in the isolated heart preparation. J Cardiovasc Pharmacol 5:848–855PubMedGoogle Scholar
  37. 37.
    Rosenoff SH, Brooks E, Bostick F, Young RC (1975) Alterations in DNA synthesis in cardiac tissue induced by adriamycin in vivo — relationship to fatal toxicity. Biochem Pharmacol 24:1898–1901CrossRefPubMedGoogle Scholar
  38. 38.
    Sawada H, Dohmae N, Tashima M, Usui T, Konishi H, Kita K, Ohkubo T, Uehara N, Uchino H (1980) Chronic cardiotoxicity of adriamycin and possible prevention by coenzyme Q10 in rabbits. Biomed Clin Aspects Coenzyme Q 2:189–204Google Scholar
  39. 39.
    Skovsgaard T, Friche E (1982) Circumvention of resistance to daunorubicin. In: Anthracyclines and cancer therapy. Proceedings of a Symposium, Ronneby Brunn, Sweden. Excerpta Medica:39–48Google Scholar
  40. 40.
    Slater LM, Murray SL, Wetzel MW, Wisdom RM, DuVall EM (1983) Verapamil restoration of daunorubicin responsiveness in daunorubicin-resistant Ehrlich ascites carcinoma. J Clin Invest 70:1131–1134Google Scholar
  41. 41.
    Suzuki T, Kanda H, Kawai Y, Tominaga K, Murata K (1979) Cardiotoxicity of anthracycline antineoplastic drugs. Clinicopathological and experimental studies. Jap Circ J 43:1000–1008PubMedGoogle Scholar
  42. 42.
    Tsuruo T, Iida H, Nojiri M, Tsukagoshi S, Sakurai Y (1983) Potentiation of chemotherapeutic effect of vincristine in vincristine resistant tumor bearing mice by calmodulin inhibitor clomipramine. J Pharmacobiodyn 6:145–147PubMedGoogle Scholar
  43. 43.
    Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y (1981) Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41:1967–1972PubMedGoogle Scholar
  44. 44.
    Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y (1983) Potentiation of vincristine and adriamycin effects in human hemopoietic tumor cell lines by calcium antagonists and calmodulin inhibitors. Cancer Res 43:2267–2272PubMedGoogle Scholar
  45. 45.
    Tsuruo T, Iida H, Yamashiro M, Tsukagoshi S, Sakurai Y (1983) Enhancement of vincristine- and adriamycin-induced cytotoxicity by verapamil in P388 leukemia and its sublines resistant to vincristine and adriamycin. Biochem Pharmacol 31:3138–3140CrossRefGoogle Scholar
  46. 46.
    Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y (1983) Increased accumulation of vincristine and adriamycin in drug-resistant P 388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res 42:4730–4733Google Scholar
  47. 47.
    Tsuruo T, Iida H, Naganuma K, Tsukagoshi S, Sakurai Y (1983) Promotion by verapamil of vincristine responsiveness in tumor cell lines inherently resistant to the drug. Cancer Res 43:808–813PubMedGoogle Scholar
  48. 48.
    Tsuruo T, Iida H, Nojiri M, Tsukagoshi S, Sakurai Y (1983) Circumvention of vincristine and adriamycin resistance in vitro and in vivo by calcium influx blockers. Cancer Res 43:2905–2910PubMedGoogle Scholar
  49. 49.
    Villani F, Guidani A, Favalli L, Chiari C, Monti E, Piccinini F (1981) Role of cell calcium in the early and delayed cardiotoxicity of anthracyclines. Proc A Assoc Cancer Res 22:30Google Scholar
  50. 50.
    Wikman-Coffelt J, Rapcsak M, Sievers R, Rouleau JL, Parmley WW (1983) Verapamil, propranolol, and hydralazine protect against the acute cardiac depression induced by adriamycin. Cardiovasc Res 17:43–49PubMedGoogle Scholar
  51. 51.
    Young DM, Mettler FP, Fioravanti JL (1975/1976) Adriamycin, verapamil and calcium metabolism. Proc Am Assoc Cancer Res 16 und 17:90Google Scholar
  52. 52.
    Zähringer J (1983) Gen-Expression und Protein-Synthese im normalen Herzmuskel und bei der Adriamycin-Kardiomyopathie. Fortschriff der Med 101:805–807Google Scholar

Copyright information

© Dr. Dietrich Steinkopff Verlag 1985

Authors and Affiliations

  • B. Maisch
    • 1
  • O. Gregor
    • 1
  • M. Zeuss
    • 1
  • K. Kochsiek
    • 1
  1. 1.Medizinische UniversitätsklinikWürzburgGermany

Personalised recommendations